Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28821831 | 1.00 | TP53 (0.44) | TP53MAPTPOLBLMNANQO2 | |
| SCHEMBL28821832 | 1.00 | TP53 (0.44) | TP53MAPTPOLBLMNANQO2 | |
| SCHEMBL25316346 | 0.94 | TP53 (0.44) | TP53MAPTPOLBLMNANQO2 | |
| SCHEMBL4869296 | 0.94 | TP53 (0.44) | TP53MAPTPOLBLMNANQO2 | |
| SCHEMBL30493626 | 0.94 | TP53 (0.44) | TP53MAPTPOLBLMNANQO2 | |
| SCHEMBL4867636 | 0.82 | MAPT (0.47) | TP53MAPTPOLBLMNAMGAT2 | |
| SCHEMBL16785608 | 0.81 | NQO2 (0.44) | TP53MAPTPOLBLMNANQO2 | |
| SCHEMBL4869505 | 0.81 | MAPT (0.41) | TP53MAPTPOLBLMNAMGAT2 | |
| SCHEMBL4866364 | 0.81 | MAPT (0.41) | TP53MAPTPOLBLMNAMGAT2 | |
| SCHEMBL16238512 | 0.79 | MAPT (0.48) | TP53MAPTPOLBLMNANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019961-A1 | Estrogen receptor ligands | GPER1, ESR2, ESR1 | TP53 848/4885MAPT 3994/4885POLB 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.